Abstracts
PMH3 ANTIDEPRESSANT PROPHYLAXIS FOR POST-STROKE
University of Cincinnati, Cincinnati, OH, USA, 2 Peking Univeristy, Beijing, Beijing, China OBJECTIVES: Given the high incidence of post-stroke depression (PSD), its serious sequalae, and inherent problems with diagnosis, prophylactic use of antidepressants may be a viable management strategy in patients experiencing stroke. The purpose of this study was to assess the prophylactic effects of antidepressants in non-depressed patients with stroke. METHODS: A meta-analysis of randomized placebo-controlled trials (RCTs) evaluating the prophylactic effects of antidepressants in non-depressed patients with stroke was conducted. Literature searches in MEDLINE, PubMed, CINAHL, PsycINFO, EMBASE, Cochrane library, and CNKI from 1950 to August 2006 were used to identify the relevant studies. Outcome measures included the occurrence rate of newly developed PSD cases and severity of depressive symptoms as indicated by mean depression rating scales scores. The effect size was presented as rate difference (RD) or weighted mean difference (WMD). RESULTS: From 10 RCTs, a total of 703 non-depressed patients after stroke were identified. The pooled occurrence rate of newly developed PSD cases in the intervention and control groups were 12.54% (41/327) and 29.17% (91/312), respectively (pooled RD = −0.17, 95% CI: −0.26 to −0.08). Prophylactic effects of antidepressants were not related to duration of use (coefficient of Pearson' correlation [ã] = 0.57, p = 0.11). CONCLUSION: Antidepressant prophylaxis is associated with a significant reduction in the occurrence rate of newly developed PSD, suggesting antidepressants may be considered along with other vascular preventive strategies in management of stroke patients.
PMH4 ADVERSE EVENT PROFILE ASSOCIATED WITH OFF-LABEL USE OF ANTIPSYCHOTIC MEDICATIONS
Abbass I, Chen H University of Houston, Houston, TX, USA OBJECTIVES: With 50-70% antipsychotic prescriptions written for off-label purposes, the objective of this study is to explore the pattern and the outcomes of adverse events (ADEs) associated with antipsychotic off-label use. METHODS: A retrospective pharmaco-vigilance analysis was conducted using the FDA Adverse Event Reporting System (AERS) data between April 2004 and March 2006. ADE cases associated with antipsychotic medications were first identified based on the role of the medication in precipitating the ADEs (primary and secondary suspects) and then categorized according to their intended indications as off-label/on-label uses. Thereafter, the most frequently reported off-label antipsychotic uses associated with ADEs were explored, and their clinical outcomes were examined and compared with on-label antipsychotic ADE cases. RESULTS: Out of 27,700 ADEs involving antipsychotic medications, antipsychotics were the primary suspect in 7519 cases and secondary suspect in 2409 cases (Total: 9928). Atypical antipsychotics accounted for majority of the cases (9122, 91.8%) with clozapine (2983, 30.1%) being the most frequently reported antipsychotic medication followed by quetiapine (2186, 22.0%) and risperidone (2153, 21.7%). Off-label use afflicted half of the reported ADEs cases (4767, 48%). The top three reported offlabel indications associated with ADEs include psychotic and schizoaffective disorders (1372, 28.8%), mood disorders (1105, 23.2%) and cognitive disorders (406, 8.5%). These ADEs could result into severe clinical outcomes. Of total 4767 ADEs associated with off-label use, (1942, 40 .7%) involved hospitalizations and (1043, 21.9% ) deaths. Similar pattern of clinical outcomes were found in ADE cases associated with on-label antipsychotic use. CONCLUSION: Most of the off-label antipsychotic-related ADEs reported to FDA is associated with using atypical antipsychotic medications for treating schizoaffective disorder, bipolar disorder, depression and dementia. More than half of these ADEs resulted in severe clinical outcomes such as hospitalizations and death. Therefore, the risk benefit ratio should be seriously considered when physicians prescribe antipsychotics for off-label purposes. 
METHODS:
We conducted a retrospective database analysis on episodes of care initiated after 1/1/2000 using data from MediCal. Our analysis included episodes for patients 18 years of age or older, diagnosed with schizophrenia, who switched medications after a minimum "wash out" period of 15 days and had no evidence of diabetes in the previous 6 months. We used a simultaneous bivariate probit model to estimate the risk of TED in patients treated with AAP in comparison to TAP. If the error
